<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001998</url>
  </required_header>
  <id_info>
    <org_study_id>103A</org_study_id>
    <secondary_id>AR-90-01-002</secondary_id>
    <nct_id>NCT00001998</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)</brief_title>
  <official_title>Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human&#xD;
      subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of&#xD;
      4 dose levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nystatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Positive HIV antibody test.&#xD;
&#xD;
          -  Diagnosis of AIDS-related complex (ARC).&#xD;
&#xD;
          -  CD4+ cell count between 100 and 300 cells/mm3.&#xD;
&#xD;
          -  Estimated life expectancy of at least 6 months.&#xD;
&#xD;
          -  Normal neurological status.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Active opportunistic infection requiring ongoing therapy except patients being treated&#xD;
             topically for oral thrush.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active opportunistic infection.&#xD;
&#xD;
          -  Known hypersensitivity to polyene antibiotics.&#xD;
&#xD;
          -  Unwillingness to sign an informed consent or to be in compliance of protocol&#xD;
             requirements.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 72 hours of study entry:&#xD;
&#xD;
          -  Biologic response modifier agents.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents.&#xD;
&#xD;
          -  Potential nephrotoxins.&#xD;
&#xD;
          -  Potential neutropenic agents.&#xD;
&#xD;
          -  Rifampin or rifampin derivatives.&#xD;
&#xD;
          -  Systemic anti-infectives.&#xD;
&#xD;
          -  Phenytoin or barbiturates (inducers of microsomal enzymes).&#xD;
&#xD;
          -  All systemic medications.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 72 hours prior to study entry:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Active alcohol or drug abuse unless they have been off drugs and/or alcohol for two weeks&#xD;
        prior to start of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Twelve Oaks Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rios A, Crofoot GE, Lenk R, Hayman A, Rosenblum M, Lopez-Berestein G. A phase 1 single dose safety evaluation and pharmacokinetic (Pkc) study of nystatin-liposomal formulation nystatin-LF i.v. in patients with HIV infection. Int Conf AIDS. 1992 Jul 19-24;8(3):127 (abstract no PuB 7473)</citation>
  </reference>
  <verification_date>November 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Nystatin</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nystatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

